آلمتوزومب (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "آلمتوزومب" in Persian language version.

refsWebsite
Global rank Persian rank
2nd place
2nd place
4th place
5th place
1st place
1st place
399th place
104th place
3,823rd place
1,188th place
447th place
382nd place

doi.org

  • Costelloe L; Jones J; Coles A (2012). "Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis". Expert Review of Neurotherapeutics. 12 (3): 335–341. doi:10.1586/ern.12.5. PMID 22364332.
  • Aranha AA; Amer S; Reda ES; Broadley SA; Davoren PM (2013). "Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review". Endocrine Practice. 19 (5): 1–25. doi:10.4158/EP13020.RA. PMID 23757618.
  • Wehrum T; Beume L-A; Stich O; Mader I; Mäurer M; Czaplinski A; Weiller C; Rauer S (2018). "Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis". Neurology. 90 (7): e601–e605. doi:10.1212/WNL.0000000000004950. PMID 29352101.
  • Azevedo CJ; Kutz C; Dix A; Boster A; Sanossian N; Kaplan J (2019). "Intracerebral haemorrhage during alemtuzumab administration". The Lancet. Neurology. 18 (4): 329–331. doi:10.1016/S1474-4422(19)30076-6. PMID 30777657.

drugs.com

  • "Alemtuzumab Monograph for Professionals". Drugs.com (به انگلیسی). American Society of Health-System Pharmacists. Archived from the original on 4 November 2019. Retrieved 15 July 2019.

fda.gov

medicines.org.uk

  • «نسخه آرشیو شده». بایگانی‌شده از اصلی در ۶ مه ۲۰۲۱. دریافت‌شده در ۲۰ اوت ۲۰۱۹.

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Costelloe L; Jones J; Coles A (2012). "Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis". Expert Review of Neurotherapeutics. 12 (3): 335–341. doi:10.1586/ern.12.5. PMID 22364332.
  • Aranha AA; Amer S; Reda ES; Broadley SA; Davoren PM (2013). "Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review". Endocrine Practice. 19 (5): 1–25. doi:10.4158/EP13020.RA. PMID 23757618.
  • Wehrum T; Beume L-A; Stich O; Mader I; Mäurer M; Czaplinski A; Weiller C; Rauer S (2018). "Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis". Neurology. 90 (7): e601–e605. doi:10.1212/WNL.0000000000004950. PMID 29352101.
  • Azevedo CJ; Kutz C; Dix A; Boster A; Sanossian N; Kaplan J (2019). "Intracerebral haemorrhage during alemtuzumab administration". The Lancet. Neurology. 18 (4): 329–331. doi:10.1016/S1474-4422(19)30076-6. PMID 30777657.

web.archive.org

  • "Alemtuzumab Monograph for Professionals". Drugs.com (به انگلیسی). American Society of Health-System Pharmacists. Archived from the original on 4 November 2019. Retrieved 15 July 2019.
  • «نسخه آرشیو شده». بایگانی‌شده از اصلی در ۶ مه ۲۰۲۱. دریافت‌شده در ۲۰ اوت ۲۰۱۹.